Skip to main content Skip to main navigation menu Skip to site footer
Global Cardiology

eISSN 2975-2728

  • About the Journal
  • Editorial Board
  • Publication Ethics
  • || New papers ||
  • Current
  • Archives
  • Special Issues
    • Overview
  • Copyright & Licensing
  • Register
  • Login
  • Search
  • Contacts
  • News

Editor-in-Chief: Andrew J.S. Coats, Australia

Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review

    Muhammad Hamza Dawood, Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Wilhelm Haverkamp
    2025-12-31
    https://doi.org/10.4081/cardio.2025.91
    639
    PDF: 219
    HTML: 34
  • The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis

    Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler
    2024-06-28
    https://doi.org/10.4081/cardio.2024.35
    3123
    PDF: 756
    Conflict of interest: 346
    SUPPLEMENTARY MATERIAL: 291
    HTML: 86
  • Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial

    Wolfram Doehner, Tim Friede, Frank Edelmann, Ulf Landmesser, Sebastian Winkler, Burkert Pieske, Fabian Knebel, Sebastian Kelle, Diethelm Tschöpe, Antje Meyer, Nadja Jauert, Marius Placzek, Jeanette Schulz-Menger, Stephan von Haehling, Stefan D. Anker
    2025-12-31
    https://doi.org/10.4081/cardio.2025.89
    373
    PDF: 118
    Appendix: 37
    HTML: 11
  • Sex-based differences in characteristics, management, and outcomes in heart failure with reduced ejection fraction

    Christian Basile, Stefan D. Anker, Gianluigi Savarese
    2025-06-30
    https://doi.org/10.4081/cardio.2025.73
    973
    PDF: 318
    Supplementary: 191
    Appendix: 141
    HTML: 98
  • The scientific targets: the myocardium, the vasculature and the body’s response to heart failure

    Rafael Vidal-Pérez, Ewa A. Jankowska
    2024-03-28
    https://doi.org/10.4081/cardio.2024.19
    2853
    PDF: 296
    HTML: 25
  • Obesity and left atrial function: state of the art

    Ahmed Mustafa Rashid, Muhammad Shahzeb Khan, Fawaz Alenezi, Stefan D. Anker, Fabian Knebel
    2026-03-31
    https://doi.org/10.4081/cardio.2026.96
    753
    PDF: 272
    HTML: 94
  • Biological plausibility and implications of obesity associated valvular heart diseases

    Francesco Fioretti, Brian R. Lindman, Javed Butler
    2024-11-05
    https://doi.org/10.4081/cardio.2024.49
    2810
    PDF: 850
    HTML: 27
  • Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients

    Javed Butler, Sanjiv J. Shah, Melissa Magwire, Carlos Campos, Muhammad Shariq Usman, Anthony Hoovler, Anup Sabharwal, Barry A. Borlaug
    2024-06-28
    https://doi.org/10.4081/cardio.2024.38
    2228
    PDF: 616
    SUPPLEMENTARY MATERIAL: 338
    GRAPHICAL ABSTRACT: 288
    HTML: 53
  • Beyond trial neutrality: treatment discontinuation and the hidden signal in SPIRIT-HF trial

    Viana Copeland, Andrew J.S. Coats
    2026-03-31
    https://doi.org/10.4081/cardio.2026.100
    1145
    PDF: 307
    HTML: 144
  • Optimized heart failure therapy in patients with very advanced cancer in palliative care: dosing strategies from the EMPATICC trial

    Markus S. Anker, Sven Bercker, Ulrich Laufs, Michael Böhm, Bela Merkely, Monika Diek, Tim Heise, Martin Hellmich, Marius Placzek, Tim Friede, Stefan D. Anker, Lorenz Lehmann, Ulf Landmesser, Dominik P. Modest, Muhammad Shahzeb Khan, Amir A. Mahabadi, Matthias Totzeck, Mitra Tewes, Muhammad Sameer Arshad, Raluca Mincu, Javed Butler, Ulrich Keller, Johann Ahn, Lars Bullinger, Tienush Rassaf
    2025-08-20
    https://doi.org/10.4081/cardio.2025.78
    585
    PDF: 461
    Appendix: 245
    HTML: 70
  • Bridging the gap between study outcomes and real-world results. Algorithm-driven management in a rural cardioMEMS population

    Marc Atzenhoefer, Elizabeth Dille, Rebecca Steinke, Nicole Weigert, Keri Sabel, Kirsten Rasmussen
    2025-04-16
    https://doi.org/10.4081/cardio.2025.63
    3685
    PDF: 805
    HTML: 51
  • Defining iron replete status in patients with heart failure treated with intravenous iron

    Khawaja M. Talha, Javed Butler, Stephan von Haehling, Mitja Lainscak, Piotr Ponikowski, Stefan D. Anker
    2023-12-21
    https://doi.org/10.4081/cardio.2023.17
    3302
    pdf: 443
    HTML: 69
  • The effect of sauna on cardiac and skeletal muscle function in patients with HFpEF (SAUNA-HFpEF): rationale and design

    Tarek Bekfani, Kris G. Vargas, Flor Gomez, Alexander Schmeisser, Ruediger C. Braun-Dullaeus
    2025-06-30
    https://doi.org/10.4081/cardio.2025.67
    2735
    PDF: 572
    HTML: 140
1 - 13 of 13 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a Scientific paper
  • How to write a Review article
  • Article Processing Charge

reviewers

FOR REVIEWERS
  • How to Review

indexing

INDEXING
  • DOAJ
  • Google Scholar
  • OpenAlex
  • Scilit
  • Analytics

iCARDIO

May 1 marked the release of the #iCARDIO Guidelines on Heart Failure, now live in Global Cardiology. This global-first effort brings flexible, practical guidance to frontline providers managing #heartfailure in any setting. www.globalcardiology.info/site/article... #GlobalHealth #cardiosky

[image or embed]

— iCardio (@icardio.bsky.social) May 13, 2025 at 8:26

Keywords

Vol. 4 No. 1 (2026)
Draft Document for Public Consultation: iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease Management 2026

Ischemic heart disease (IHD) remains the leading cause of morbidity and mortality worldwide.  Coronary artery disease (CAD) encompasses any pathological process capable of compromising myocardial perfusion and although numerous etiologies exist, including vasculitis, spontaneous coronary artery dissection, and coronary embolism, the majority of CAD is attributable to coronary atherosclerosis, which constitutes the focus of this document. For practical purposes, CAD is considered present when any degree of atherosclerotic involvement...

Writing Task Force | iCARDIO-Alliance
5 February 2026
Vol. 4 No. 1 (2026)
Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: a state-of-the-art review

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide, affecting more than 30% of adults and up to 70–90% of individuals with obesity or type 2 diabetes mellitus. Cardiovascular disease (CVD) represents the leading cause of mortality in this population. MASLD is increasingly recognized as an independent cardiovascular risk factor beyond traditional metabolic comorbidities. This narrative review summarizes epidemiologic,...

Aimen Shafiq et al.
10 April 2026
Global Cardiology

is an Open Access, peer-reviewed journal published online by PAGEPress®, Pavia, Italy.
[Website continuously updated]

eISSN: 2975-2728

Info

  • About
  • Editorial Board
  • News

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy